I
This company utilizes its EVOBodies™ platform, combining AI and biological tools, to generate single-domain antibodies (VHH) and minibinders against any antigen. They offer bio-pharmaceutical companies a predictable, accelerated workflow to obtain precise antigen-binding molecules in six weeks. This service streamlines research processes by eliminating the uncertainty and time associated with traditional antibody generation campaigns.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- This company utilizes its EVOBodies™ platform, combining AI and biological tools, to generate single-domain antibodies (VHH) and minibinders against any antigen. They offer bio-pharmaceutical companies a predictable, accelerated workflow to obtain precise antigen-binding molecules in six weeks. This service streamlines research processes by eliminating the uncertainty and time associated with traditional antibody generation campaigns.